Medtech1.com: Great Information, Real Community, Better Living.
 Register
 Login
 Main Page
 MedTech News
Tech & Innovation
Living With a Device
 Education Center
Diagnostic Tests
Conditions
Procedures
Women's Health
Companies
Online Resources
Video Library
Dr. Christopher Kwolek  MedTech  Hero™
Dr. Christopher Kwolek:
Pioneering New Blood Clot Treatments.
About Heroes
 Join the Discussion in  Our Forums
 Community
MedTech1 Forums
 Advocacy Center
Contact Congress
Find a Patient Group
 Bookmark Us
 
advertisement
Search the Body1 Network
February 24, 2019  
MEDTECH NEWS: Latest Headlines

  • Print this Article
  • Email this Article
  • Links/Reprints
  • Discuss this Article
  • Drug Doesn't Cut Heart Patient Risk


    November 05, 2002

    CHICAGO (AP) - A promising anti-clotting drug does not improve hospitalized heart attack patients' chances of surviving a year when it is added to the standard treatment, a study found.

    The disappointing results came in a follow-up international study of 16,588 patients who received intravenous doses of a standard clot-busting medicine with or without the newer drug, abciximab, or ReoPro.

    ReoPro, known as a "super aspirin," helps keep blood particles called platelets from sticking together and forming a clot that can cause a heart attack. The older drug, reteplase, attacks different substances in blood clots.

    ReoPro's primary use is for patients undergoing angioplasty, a technique that opens clogged blood vessels. In a study reported last year and funded by ReoPro's U.S. marketers Centocor and Eli Lilly, researchers tried using it in a different way, combining it with a reduced dose of reteplase in patients who had just suffered a heart attack. The combination treatment lowered patients' 30-day risk of a repeat heart attack by 30 percent.

    But in the follow-up study, the death rates after a year were identical - nearly 700 patients in both groups died, or about 8 percent in each.

    The findings were published in Wednesday's Journal of the American Medical Association.

    The researchers said the reasons for the findings are unclear.

    Dr. A. Michael Lincoff of Cleveland Clinic, who helped conduct the study, said ReoPro may still be a useful drug because it can reduce the short-term risk of repeat heart attacks and has other heart benefits.

    ---=

    On the Net:

    JAMA: http://jama.ama-assn.org


    Last updated: 05-Nov-02

       
    Interact on Medtech1
    DISCUSS THIS ARTICLE
    Ask a question or share your opinions on this topic with others in the Body1 community.
     
    Latest Headlines Archives
    Going for Gold With a Novel Interventional Radiology Treatment for Pancreatic Cancer

    Foam Bones: A New Generation of Biomedical Implants

    Tongue-Controlled Wheelchair Holds Hope for the Quadriplegics and Others

    Can ‘Report Cards’ on Clinics Improve Patient Care?

    Going out Green – Boomers Reinvent the Funeral Industry

    Next 5 Features ...

    More Headlines ...

     
    Home About Us Press Jobs Advertise With Us Contact Us
    advertisement
    © 2019 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.